If you have further questions, please contact the HEALTH NCP in your region/country!
Budget: € 6 billion over 7 years (2007 – 2013).
Objective: to improve the health of European citizens; boost the competitiveness of health-related industries and businesses, help find solutions to global health issues such as anti-microbial resistance, HIV/AIDS, malaria, tuberculosis, emerging pandemics...
The focus will be on biotechnology, the development of tools and technologies for human health, translating research into useful application for human health, and optimising the delivery of health care to European citizens.
More about the HEALTH program on the CORDIS website…
• WHO can participate?
• WHEN can you submit a project?
• WHAT are the budgets, funding schemes, research themes?
• HOW can you participate, how to start, how to prepare?
The “SMEs go Health” network of partners can offer you their support in building a project as a coordinator or participate in a project as a partner.
Go to "SMEs go Health" services
Find out which research areas are financed by looking in the HEALTH Work Programme. Check the open Calls for Proposals to see if one of the topics supported fits your research objectives.
There are currently no Health Calls open
The European Technology Platforms (ETP) will play an important role in the evolution of European R&D: they will help to define the research objectives of the EU’s 7th Framework Programme for Research and Technological Development.
They regroup, in a defined key-sector, research and innovation actors – industries, SMEs, public and private research. They are coordinated by industrial leaders on the sector. This structure will allow the developing of a useful R&D policy that will be accepted by the industry.
The European Technology Platforms should:
COLIPA NanoMedicine - Nanotechnologies for Medical Applications IMI - Innovative Medicines Initiative Plants for the future (KBBE)In a unique joint effort, the European cosmetic industry has decided to match research funds made available by the European Commission under the 7th RTD Framework Programme.
The European Commission launched a Call for Proposals on 30 July 2009 asking researchers to submit proposals on the development of a strategy towards alternative solutions to animal testing in the field of repeated dose systemic toxicity. The European cosmetic industry has committed to match the funding given by the European Commission, making a total of EUR 50 million available for this theme.
Up to 7 projects will be selected by the European Commission, according to criteria defined by this Call for Proposals. Selected projects can benefit from funding from both the European Commission and the cosmetic industry, providing up to 100% of the total funding for each project. The available funds make up a total of EUR 50 million, ith half being provided by the European Commission and half by the cosmetic industry.
To view the summary of the Call for Proposals, please click here.
For the Colipa Statement on the on Research funding for Commission Call, please click here.
The detailed programme of two information events around the Commission Call will be held at the occasion of the 7th World Congress on "Alternatives and Animal Use in Life Sciences''.
For more information please click here
The aging population, the high expectations towards quality of life and the changing lifestyle of the European society leads to the need for improved, more efficient, and affordable medical care.
Europe has a strong position in the novel area of NanoMedicine, using nanotechnology for medical applications. Industry starts to take up these promising opportunities. Nevertheless, the area of NanoMedicine is quite fragmented and will strongly benefit from a co-ordination at European level.
Dissemination of knowledge, regulatory and IPR issues, standardisation, ethical, safety, environmental and toxicity concerns as well as public perception in general and the input from other stakeholders like insurance companies or patient organisations will play an important role.
Published documents can be found in the right column.
The overall objective of IMI is to remove bottlenecks hampering the efficiency of the development of new medicines, and where research is the key, thereby enabling the European biopharmeceutical industry to become world leaders.
At the same time, by pooling resources from all stakeholders (industry, academia, SMEs, regulatory authorities, healthcare providers, patient organisations), this initiative is expected to provide faster access to better medicines for European citizens.
Published documents can be found in the right column.
The primary aim of funding the 'Food, Agriculture and Fisheries, and Biotechnology' research theme under the Seventh Framework Programme (FP7) is to build a European Knowledge Based Bio-Economy (KBBE).
The EU Member States have earmarked more than € 1.9 billion for funding this theme over the duration of FP7.
The 'Food, Agriculture and Fisheries, and Biotechnology' theme is built around three major activities':
Subscribe to our news feed